|
1
|
Hernández-Arteaga AC, Ojeda-Galván HJ, Rodríguez-Aranda MC, Toro-Vázquez JF, Sánchez J, José-Yacamán M, Navarro-Contreras HR. Determination of the denaturation temperature of the Spike protein S1 of SARS-CoV-2 (2019 nCoV) by Raman spectroscopy. SPECTROCHIMICA ACTA. PART A, MOLECULAR AND BIOMOLECULAR SPECTROSCOPY 2022; 264:120269. [PMID: 34418811 PMCID: PMC8359494 DOI: 10.1016/j.saa.2021.120269] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Revised: 07/15/2021] [Accepted: 08/07/2021] [Indexed: 05/14/2023]
Abstract
In the present work the temperature response of the constitutive S1 segment of the SARS-CoV-2 Spike Glycoprotein (GPS) has been studied. The intensity of the Raman bands remained almost constant before reaching a temperature of 133 °C. At this temperature a significant reduction of peak intensities was observed. Above 144 °C the spectra ceased to show any recognizable feature as that of the GPS S1, indicating that it had transformed after the denaturation process that it was subjected. The GPS S1 change is irreversible. Hence, Raman Spectroscopy (RS) provides a precision method to determine the denaturation temperature (TD) of dry powder GPS S1. The ability of RS was calibrated through the reproduction of TD of other well studied proteins as well as those of the decomposition temperature of some amino acids (AA). Through this study we established a TD of 139 ± 3 °C for powder GPS S1 of SARS-CoV-2.
Collapse
Affiliation(s)
- A C Hernández-Arteaga
- Coordinación para la Innovación y la Aplicación de la Ciencia y la Tecnología, Universidad Autónoma de San Luis Potosí, Av. Sierra Leona #550, Col. Lomas 2a. Sección, CP 78210 San Luis Potosí, SLP, México
| | - H J Ojeda-Galván
- Coordinación para la Innovación y la Aplicación de la Ciencia y la Tecnología, Universidad Autónoma de San Luis Potosí, Av. Sierra Leona #550, Col. Lomas 2a. Sección, CP 78210 San Luis Potosí, SLP, México; Centro de Investigación en Ciencias de la Salud y Biomedicina (CICSaB), Universidad Autónoma de San Luis Potosí, Av. Sierra Leona #550, Col. Lomas 2a. Sección, CP 78210 San Luis Potosí, SLP, México.
| | - M C Rodríguez-Aranda
- Coordinación para la Innovación y la Aplicación de la Ciencia y la Tecnología, Universidad Autónoma de San Luis Potosí, Av. Sierra Leona #550, Col. Lomas 2a. Sección, CP 78210 San Luis Potosí, SLP, México
| | - J F Toro-Vázquez
- Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava 6, Zona Universitaria, San Luis Potosí 78290, México
| | - J Sánchez
- Applied Physics and Materials Science Department and Center for Material Interfaces Research and Applications (MIRA), Northern Arizona University, Flagstaff, AZ, USA
| | - M José-Yacamán
- Coordinación para la Innovación y la Aplicación de la Ciencia y la Tecnología, Universidad Autónoma de San Luis Potosí, Av. Sierra Leona #550, Col. Lomas 2a. Sección, CP 78210 San Luis Potosí, SLP, México; Applied Physics and Materials Science Department and Center for Material Interfaces Research and Applications (MIRA), Northern Arizona University, Flagstaff, AZ, USA
| | - H R Navarro-Contreras
- Coordinación para la Innovación y la Aplicación de la Ciencia y la Tecnología, Universidad Autónoma de San Luis Potosí, Av. Sierra Leona #550, Col. Lomas 2a. Sección, CP 78210 San Luis Potosí, SLP, México.
| |
Collapse
|
|
2
|
Guebre-Xabier M, Patel N, Tian JH, Zhou B, Maciejewski S, Lam K, Portnoff AD, Massare MJ, Frieman MB, Piedra PA, Ellingsworth L, Glenn G, Smith G. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine 2020; 38:7892-7896. [PMID: 33139139 DOI: 10.1101/2020.08.18.256578] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2020] [Revised: 10/02/2020] [Accepted: 10/19/2020] [Indexed: 05/28/2023]
Abstract
There is an urgent need for a safe and protective vaccine to control the global spread of SARS-CoV-2 and prevent COVID-19. Here, we report the immunogenicity and protective efficacy of a SARS-CoV-2 subunit vaccine (NVX-CoV2373) produced from the full-length SARS-CoV-2 spike (S) glycoprotein stabilized in the prefusion conformation. Cynomolgus macaques (Macaca fascicularis) immunized with NVX-CoV2373 and the saponin-based Matrix-M™ adjuvant induced anti-S antibody that was neutralizing and blocked binding to the human angiotensin-converting enzyme 2 (hACE2) receptor. Following intranasal and intratracheal challenge with SARS-CoV-2, immunized macaques were protected against upper and lower infection and pulmonary disease. These results support ongoing phase 1/2 clinical studies of the safety and immunogenicity of NVX-CoV2327 vaccine (NCT04368988).
Collapse
Affiliation(s)
| | - Nita Patel
- Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA.
| | - Jing-Hui Tian
- Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA.
| | - Bin Zhou
- Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA.
| | | | - Kristal Lam
- Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA.
| | | | | | - Matthew B Frieman
- University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, USA.
| | - Pedro A Piedra
- Department of Molecular Virology and Microbiology, and Pediatrics, Baylor College of Medicine, Houston, TX, USA.
| | | | - Gregory Glenn
- Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA.
| | - Gale Smith
- Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA.
| |
Collapse
|